Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) EPS (Basic) (2021 - 2025)

Prime Medicine (PRME) has disclosed EPS (Basic) for 5 consecutive years, with -$0.24 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 22.58% year-over-year to -$0.24, compared with a TTM value of -$1.35 through Dec 2025, up 18.18%, and an annual FY2025 reading of -$1.35, up 18.18% over the prior year.
  • EPS (Basic) was -$0.24 for Q4 2025 at Prime Medicine, up from -$0.3 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.72 in Q4 2022 and bottomed at -$4.45 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$0.88, with a median of -$0.45 recorded in 2023.
  • The sharpest move saw EPS (Basic) soared 116.18% in 2022, then plummeted 200.0% in 2023.
  • Year by year, EPS (Basic) stood at -$4.45 in 2021, then soared by 116.18% to $0.72 in 2022, then tumbled by 200.0% to -$0.72 in 2023, then skyrocketed by 56.94% to -$0.31 in 2024, then rose by 22.58% to -$0.24 in 2025.
  • Business Quant data shows EPS (Basic) for PRME at -$0.24 in Q4 2025, -$0.3 in Q3 2025, and -$0.41 in Q2 2025.